Previous 10 | Next 10 |
Akero Therapeutics ( NASDAQ: AKRO ) shares are down 2.53% after-hours after the firm prices an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00/share for expected gross proceeds to be ~$200.0M. All of the...
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized u...
Summary Akero Therapeutics reported positive mid-stage NASH trial results. Akero immediately announced a stock offering to raise cash. Even after AKRO stock price doubled on September 13, it is still a Buy. Akero Therapeutics ( NASDAQ: AKRO ) is a biotechnolo...
Clinical-stage company Akero Therapeutics ( NASDAQ: AKRO ) commenced an underwritten public offering of $175M of shares, subject to market and other conditions. The company may also grant the underwriters a 30-day option to purchase up to an additional $26.25M of shar...
Akero Therapeutics ( NASDAQ: AKRO ), a biotech focused on nonalcoholic steatohepatitis (NASH), has gained more than ~100% in the morning hours Tuesday lifting its peers after the company said Efruxifermin, its candidate for the liver disease, reached the main goal in a P...
Shares of the clinical-stage biotech Akero Therapeutics (NASDAQ: AKRO) were up by a staggering 110% on sky-high volume as of 9:56 a.m. ET Tuesday morning. The biotech's shares have more than doubled in price this morning in response to a positive phase 2b trial for the experimental ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Andrus Ciprian / Shutterstock.com NeuroBo Pharmaceuticals (NASDAQ: NRBO ) stock is rocketing higher on Tuesday after the company underwent a reverse stock split this morning. NRBO stock we...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Akero Therapeutics (NASDAQ: AKRO ) stock is soaring 120% and is one of today’s top trending tickers on sites like Yahoo Finance . The rally was sparked by the company’s release of positive data on it...
Most investors seemed to enjoy Monday's move higher for the stock market, and Wall Street came in Tuesday morning with hopes that a late-summer rally could continue. Yet higher inflation than expected put cold water on thoughts that signs of weakening price pressures could take away one sou...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! News moving stocks this morning include clinical trial updates, earnings reports...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...